Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Assets Average (2025)

Historic Assets Average for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $156.0 million.

  • Silence Therapeutics' Assets Average fell 7982.24% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.0 million, marking a year-over-year decrease of 7982.24%. This contributed to the annual value of $161.0 million for FY2024, which is 2756.22% up from last year.
  • Latest data reveals that Silence Therapeutics reported Assets Average of $156.0 million as of Q3 2025, which was down 7982.24% from $175.3 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Assets Average high stood at $773.2 million for Q3 2024, and its period low was $156.0 million during Q3 2025.
  • Moreover, its 5-year median value for Assets Average was $476.0 million (2023), whereas its average is $417.9 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 8886.44% in 2022, then tumbled by 7982.24% in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Assets Average stood at $262.4 million in 2021, then soared by 88.86% to $495.5 million in 2022, then dropped by 3.94% to $476.0 million in 2023, then grew by 7.54% to $511.9 million in 2024, then tumbled by 69.52% to $156.0 million in 2025.
  • Its last three reported values are $156.0 million in Q3 2025, $175.3 million for Q2 2025, and $194.0 million during Q1 2025.